drugset
drugset / Trial / NCT00003590

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

NCT00003590 ↗

Phase 2 Completed 29 enrolled SWOG Cancer Research Network Eastern Cooperative Oncology Group · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.

Timeline

Start
1998-11
Primary completion
2008-12
Completion
2011-07

Publications

  • Results Swinnen LJ, Rankin C, Rushing EJ, et al.: Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). [Abstract] J Clin Oncol 27 (Suppl 15): A-2063, 2009.

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxyurea Other / unclassified 20 mg/kg Oral

Indications

meningioma